Literature DB >> 19949913

Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure.

Yoshihisa Okazaki1, Can Zheng, Meihua Li, Masaru Sugimachi.   

Abstract

In an earlier study we demonstrated the beneficial effect of direct vagal electrical stimulation on cardiac remodeling and survival. In the study reported here, we attempted to reproduce the effect of vagal enhancement through the administration of an acetylcholinesterase inhibitor, donepezil. A rat model of heart failure following extensive healed myocardial infarction was used. Compared to their nontreated counterparts, rats given donepezil (5 mg/kg/day) in their drinking water had a smaller biventricular weight (3.40 +/- 0.13 vs. 3.02 +/- 0.21 g/kg body weight, P < 0.05), and maximal rate of rise (3256 +/- 955 vs. 3822 +/- 389 mmHg/s, P < 0.05) and the end-diastolic value (30.1 +/- 5.6 vs. 23.2 +/- 5.7 mmHg, P < 0.05) of left ventricular pressure were improved. Neurohumoral factors were suppressed in donepezil-treated rats (norepinephrine 1885 +/- 1423 vs. 316 +/- 248 pg/ml, P < 0.01; brain natriuretic peptide 457 +/- 68 vs. 362 +/- 80 ng/ml, P < 0.05), and the high-frequency component of heart rate variability showed a nocturnal increase. These findings indicated that donepezil reproduced the anti-remodeling effect of electrical vagal stimulation. Further studies are warranted to evaluate the clinical usefulness of donepezil in heart failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19949913     DOI: 10.1007/s12576-009-0071-5

Source DB:  PubMed          Journal:  J Physiol Sci        ISSN: 1880-6546            Impact factor:   2.781


  25 in total

1.  Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1alpha.

Authors:  Yoshihiko Kakinuma; Motonori Ando; Masanori Kuwabara; Rajesh G Katare; Koji Okudela; Masanobu Kobayashi; Takayuki Sato
Journal:  FEBS Lett       Date:  2005-04-11       Impact factor: 4.124

2.  Decreased heart rate variability and its association with increased mortality after acute myocardial infarction.

Authors:  R E Kleiger; J P Miller; J T Bigger; A J Moss
Journal:  Am J Cardiol       Date:  1987-02-01       Impact factor: 2.778

3.  Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure.

Authors:  B Casadei; J Conway; C Forfar; P Sleight
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

4.  Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats.

Authors:  Meihua Li; Can Zheng; Takayuki Sato; Toru Kawada; Masaru Sugimachi; Kenji Sunagawa
Journal:  Circulation       Date:  2003-12-08       Impact factor: 29.690

5.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.

Authors:  M Packer
Journal:  J Am Coll Cardiol       Date:  1992-07       Impact factor: 24.094

6.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

7.  Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure.

Authors:  G Venkatesh; E L Fallen; M V Kamath; S Connolly; S Yusuf
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

8.  Cholinergic stimulation improves autonomic and hemodynamic profile during dynamic exercise in patients with heart failure.

Authors:  Salvador Manoel Serra; Ricardo Vivacqua Costa; Renata Rodrigues Teixeira De Castro; Sergio Salles Xavier; Antonio Claudio Lucas Da Nóbrega
Journal:  J Card Fail       Date:  2008-12-02       Impact factor: 5.712

9.  Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation.

Authors:  Hong Wang; Man Yu; Mahendar Ochani; Carol Ann Amella; Mahira Tanovic; Seenu Susarla; Jian Hua Li; Haichao Wang; Huan Yang; Luis Ulloa; Yousef Al-Abed; Christopher J Czura; Kevin J Tracey
Journal:  Nature       Date:  2002-12-22       Impact factor: 49.962

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  22 in total

Review 1.  Pharmacologic modulation of parasympathetic activity in heart failure.

Authors:  Monali Y Desai; Mari A Watanabe; Abhay A Laddu; Paul J Hauptman
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

2.  Autonomic Dysregulation as a Therapeutic Target for Acute HF.

Authors:  Anju Bhardwaj; Mark E Dunlap
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-10

Review 3.  Methods of assessing vagus nerve activity and reflexes.

Authors:  Mark W Chapleau; Rasna Sabharwal
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

4.  Nicotinic acetylcholine receptor-mediated protection of the rat heart exposed to ischemia reperfusion.

Authors:  Spyros A Mavropoulos; Nayaab S Khan; Asaph C J Levy; Bradley T Faliks; Cristina P Sison; Valentin A Pavlov; Youhua Zhang; Kaie Ojamaa
Journal:  Mol Med       Date:  2017-06-08       Impact factor: 6.354

5.  Changes in Autonomic Nervous System Activity are Associated with Changes in Sexual Function in Women with a History of Childhood Sexual Abuse.

Authors:  Tierney K Lorenz; Christopher B Harte; Cindy M Meston
Journal:  J Sex Med       Date:  2015-05-11       Impact factor: 3.802

6.  Impact of Peripheral α7-Nicotinic Acetylcholine Receptors on Cardioprotective Effects of Donepezil in Chronic Heart Failure Rats.

Authors:  Meihua Li; Can Zheng; Toru Kawada; Masashi Inagaki; Kazunori Uemura; Tsuyoshi Akiyama; Masaru Sugimachi
Journal:  Cardiovasc Drugs Ther       Date:  2020-08-29       Impact factor: 3.727

Review 7.  Heart Failure and Cognitive Impairment: Clinical Relevance and Therapeutic Considerations.

Authors:  Tuoyo O Mene-Afejuku; Monica Pernia; Uzoma N Ibebuogu; Shobhana Chaudhari; Savi Mushiyev; Ferdinand Visco; Gerald Pekler
Journal:  Curr Cardiol Rev       Date:  2019

8.  Pyridostigmine improves cardiac function and rhythmicity through RyR2 stabilization and inhibition of STIM1-mediated calcium entry in heart failure.

Authors:  Stephen Baine; Ingrid Bonilla; Andriy Belevych; Andrei Stepanov; Lisa E Dorn; Radmila Terentyeva; Dmitry Terentyev; Federica Accornero; Cynthia A Carnes; Sandor Gyorke
Journal:  J Cell Mol Med       Date:  2021-03-23       Impact factor: 5.310

9.  An analysis of the myocardial transcriptome in a mouse model of cardiac dysfunction with decreased cholinergic neurotransmission.

Authors:  Ashbeel Roy; Aline Lara; Diogo Guimarães; Rita Pires; Eneas R Gomes; David E Carter; Marcus V Gomez; Silvia Guatimosim; Vania F Prado; Marco A M Prado; Robert Gros
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  A non-neuronal cardiac cholinergic system plays a protective role in myocardium salvage during ischemic insults.

Authors:  Yoshihiko Kakinuma; Tsuyoshi Akiyama; Kayo Okazaki; Mikihiko Arikawa; Tatsuya Noguchi; Takayuki Sato
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.